Interim report January 1 – June 30, 2005

Artimplant raised 89 MSEK through an oversubscribed share issue. CE-mark of two new products within odontology and craniomaxillofacial surgery. • Net revenue of 1.3 MSEK (1.0 MSEK) • Net profit of –19.4 MSEK (-13.3 MSEK) • Earnings per share of –0.39 SEK (-0.35 SEK) • Artimplant raised 89 MSEK through an oversubscribed share issue Events after the period • Artimplant strengthened its commercial base through CE-mark of two new products within odontology and craniomaxillofacial surgery (surgery of cranial and facial bone tissue) • Lars-Johan Cederbrant was employed as CFO A full translation of the interim report is available at the company website. For additional information, please contact: Tord Lendau, CEO, phone +46 (0)31 746 56 00, +46 (0)708 369 403, tord.lendau@artimplant.se Web site: www.artimplant.com